Eschler Asset Management LLP Has $2.78 Million Stake in Immunocore Holdings PLC Sponsored ADR $IMCR

Eschler Asset Management LLP grew its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 100.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,000 shares of the company’s stock after purchasing an additional 40,000 shares during the period. Immunocore comprises 1.9% of Eschler Asset Management LLP’s portfolio, making the stock its 14th largest holding. Eschler Asset Management LLP owned about 0.16% of Immunocore worth $2,777,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Harbour Investments Inc. grew its stake in shares of Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares in the last quarter. DNB Asset Management AS grew its stake in shares of Immunocore by 6.4% in the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock valued at $295,000 after buying an additional 488 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after buying an additional 572 shares in the last quarter. R Squared Ltd grew its stake in shares of Immunocore by 7.4% in the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after buying an additional 606 shares in the last quarter. Finally, Leonteq Securities AG bought a new stake in shares of Immunocore in the 4th quarter valued at approximately $30,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 1.2%

Shares of Immunocore stock opened at $28.96 on Friday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -52.65 and a beta of 0.74. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The stock has a 50 day moving average price of $29.61 and a two-hundred day moving average price of $32.33. Immunocore Holdings PLC Sponsored ADR has a 12-month low of $27.56 and a 12-month high of $40.71.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 earnings per share. Equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IMCR shares. Needham & Company LLC boosted their price target on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Mizuho set a $38.00 price target on Immunocore in a research note on Thursday, February 19th. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and lowered their price target for the company from $48.00 to $33.00 in a research note on Monday, March 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $56.71.

Immunocore Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.